Finding
New Uplizna data drop in myasthenia gravis, while clock ticks on IgG4 decision
Uplizna, Myasthenia Gravis, Effectiveness, Improvement
Arrowhead finds RNAi kidney disease candidate is well tolerated in phase 1/2 IgAN trial cohort
ARO-C3, IGA Glomerulonephritis, RNA Interference
AAD25: Ahead of CSU filing, Novartis’ BTK inhibitor shows sleep benefits
Chronic Spontaneous Urticaria, remibrutinib, Sleep, CSU, Novartis
In confirmation hearing, FDA nominee Martin Makary talks drug reviews, vaccines, ethics and more
United States Food and Drug Administration, Makary, Vaccines, Ethics, Advisory Committees
Drug Pricing and the Uncertain Future of the IRA Under Trump
IRA, Transplant Registry Unified Management Program, drug price, Medicare, Mediation, repeal, Changing, Uncertainty, Prices
UPDATE: DOGE quietly decreases savings estimate for 30 terminated FDA leases
Financial savings, United States Food and Drug Administration, DOGE, Estimated, leases, terminated – RoleStatus, St. Louis, DOGE ‘s
Freed Raises $30M to Transform Medical Documentation with AI-Powered Assistant
AI medical scribe, clinician burnout, administrative burden, healthcare technology, Series A funding
Lexicon stumbles on second batch of mixed results for pain drug
Dosage, lexicon, Statistical Significance
Australia steadfast on rejection of Eisai, Biogen’s Alzheimer’s therapy Leqembi
Lecanemab, Eisai, Leqembi, Alzheimer ‘s disease, Decision, Presenile dementia, Australia
5 Market Access Mistakes That Can Derail Your EU Orphan Drug Launch
EU, Market, Access, Failed, NR4A2 gene